Australia markets closed

InVivo Therapeutics Holdings Co (NVIVQ)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
0.39500.0000 (0.00%)
At close: 02:06PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.23M
Enterprise value -7.35M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.14
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.26
52-week change 3-69.47%
S&P500 52-week change 325.22%
52-week high 31.4100
52-week low 30.1500
50-day moving average 30.3816
200-day moving average 30.6227

Share statistics

Avg vol (3-month) 319.16k
Avg vol (10-day) 38.98k
Shares outstanding 53.11M
Implied shares outstanding 63.11M
Float 82.94M
% held by insiders 10.02%
% held by institutions 16.02%
Shares short (31 Jan 2024) 417.63k
Short ratio (31 Jan 2024) 40.91
Short % of float (31 Jan 2024) 40.64%
Short % of shares outstanding (31 Jan 2024) 40.57%
Shares short (prior month 29 Dec 2023) 4357

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 312 Feb 2020
Ex-dividend date 4N/A
Last split factor 21:25
Last split date 327 Apr 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-53.71%
Return on equity (ttm)-98.11%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -9.8M
Net income avi to common (ttm)-9.33M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)8.58M
Total cash per share (mrq)2.76
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)14.30
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-10.13M
Levered free cash flow (ttm)-7.03M